| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Klencke Barbara serves as a Director at TCRX and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 4 buys and 0 sells. Those positions are worth an estimated $238K at current prices.
Historically, Klencke Barbara's trades have earned a below-average insider score of 23/100 across 4 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -60.5%.
The biggest single holding is TCRX (~$238K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 20,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2024 | TCRX Tscan Therapeutics, Inc. | Director | Buy | 5,000 | $5.29 | $26,450.00 | +12.5% | -42.1% | -65.4% | |
| Aug 26, 2024 | TCRX Tscan Therapeutics, Inc. | Director | Buy | 10,000 | $5.61 | $56,100.00 | +33.3% | -20.3% | -66.7% | |
| Dec 14, 2023 | TCRX Tscan Therapeutics, Inc. | Director | Buy | 5,000 | $5.08 | $25,400.00 | +20.0% | +34.2% | -43.0% |